Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Respiratory syncytial virus entry and how to block it.

Battles MB, McLellan JS.

Nat Rev Microbiol. 2019 Feb 5. doi: 10.1038/s41579-019-0149-x. [Epub ahead of print] Review.

PMID:
30723301
2.

Iterative screen optimization maximizes the efficiency of macromolecular crystallization.

Jones HG, Wrapp D, Gilman MSA, Battles MB, Wang N, Sacerdote S, Chuang GY, Kwong PD, McLellan JS.

Acta Crystallogr F Struct Biol Commun. 2019 Feb 1;75(Pt 2):123-131. doi: 10.1107/S2053230X18017338. Epub 2019 Jan 24.

3.

Structure-Based Vaccine Antigen Design.

Graham BS, Gilman MSA, McLellan JS.

Annu Rev Med. 2019 Jan 27;70:91-104. doi: 10.1146/annurev-med-121217-094234.

PMID:
30691364
4.

Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Dec 10;8(1):17823. doi: 10.1038/s41598-018-36918-8.

5.

A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry.

Rosen O, Chan LL, Abiona OM, Gough P, Wang L, Shi W, Zhang Y, Wang N, Kong WP, McLellan JS, Graham BS, Corbett KS.

J Virol Methods. 2019 Mar;265:77-83. doi: 10.1016/j.jviromet.2018.11.009. Epub 2018 Nov 20.

PMID:
30468747
6.

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Oct 24;8(1):15701. doi: 10.1038/s41598-018-34171-7. Erratum in: Sci Rep. 2018 Dec 10;8(1):17823.

7.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18. Review. Erratum in: Lancet Infect Dis. 2018 Jul 25;:.

8.

Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity.

Hicks SN, Chaiwatpongsakorn S, Costello HM, McLellan JS, Ray W, Peeples ME.

J Virol. 2018 Jul 17;92(15). pii: e00621-18. doi: 10.1128/JVI.00621-18. Print 2018 Aug 1.

9.

Global site-specific analysis of glycoprotein N-glycan processing.

Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC.

Nat Protoc. 2018 Jun;13(6):1196-1212. doi: 10.1038/nprot.2018.024. Epub 2018 May 3.

PMID:
29725121
10.

Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Mar 7. pii: JVI.02002-17. doi: 10.1128/JVI.02002-17. [Epub ahead of print]

11.

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.

Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P, Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB, Langedijk JP, McLellan JS.

PLoS Pathog. 2018 Mar 6;14(3):e1006935. doi: 10.1371/journal.ppat.1006935. eCollection 2018 Mar.

12.

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM.

Immunity. 2018 Feb 20;48(2):339-349.e5. doi: 10.1016/j.immuni.2018.01.005. Epub 2018 Feb 3.

13.

Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses.

Olmedillas E, Cano O, Martínez I, Luque D, Terrón MC, McLellan JS, Melero JA, Más V.

EMBO Mol Med. 2018 Feb;10(2):175-187. doi: 10.15252/emmm.201708078.

14.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

15.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

16.

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.

Battles MB, Más V, Olmedillas E, Cano O, Vázquez M, Rodríguez L, Melero JA, McLellan JS.

Nat Commun. 2017 Nov 16;8(1):1528. doi: 10.1038/s41467-017-01708-9.

17.

Clinical Potential of Prefusion RSV F-specific Antibodies.

Rossey I, McLellan JS, Saelens X, Schepens B.

Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Review.

PMID:
29054341
18.

Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.

Li Z, Wang D, Gu Y, Song S, He M, Shi J, Liu X, Wei S, Li J, Yu H, Zheng Q, Yan X, Baker TS, Zhang J, McLellan JS, Li S, Xia N.

MBio. 2017 Sep 26;8(5). pii: e00787-17. doi: 10.1128/mBio.00787-17.

19.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. doi: 10.1073/pnas.1707304114. Epub 2017 Aug 14.

20.

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, Berg JVD, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S, Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A.

Nat Commun. 2017 Aug 1;8(1):167. doi: 10.1038/s41467-017-00170-x.

21.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.

22.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

23.

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.

Sci Transl Med. 2017 May 3;9(388). pii: eaaj1928. doi: 10.1126/scitranslmed.aaj1928.

PMID:
28469033
24.

Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P.

J Virol. 2017 Jun 26;91(14). pii: e00184-17. doi: 10.1128/JVI.00184-17. Print 2017 Jul 15.

25.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Erratum in: Nat Commun. 2017 Nov 29;8:16165.

26.

Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.

Gilman MS, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, Mas V, Melero JA, Wright PF, Graham BS, McLellan JS, Walker LM.

Sci Immunol. 2016 Dec 16;1(6). pii: eaaj1879. doi: 10.1126/sciimmunol.aaj1879. Epub 2016 Dec 9.

27.

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.

Ha S, Li F, Troutman MC, Freed DC, Tang A, Loughney JW, Wang D, Wang IM, Vlasak J, Nickle DC, Rustandi RR, Hamm M, DePhillips PA, Zhang N, McLellan JS, Zhu H, Adler SP, McVoy MA, An Z, Fu TM.

J Virol. 2017 Mar 13;91(7). pii: e02033-16. doi: 10.1128/JVI.02033-16. Print 2017 Apr 1.

28.

Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Melero JA, Mas V, McLellan JS.

Vaccine. 2017 Jan 11;35(3):461-468. doi: 10.1016/j.vaccine.2016.09.045. Epub 2016 Sep 28. Review.

29.

Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.

Más V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terrón MC, Luque D, Melero JA, McLellan JS.

PLoS Pathog. 2016 Sep 9;12(9):e1005859. doi: 10.1371/journal.ppat.1005859. eCollection 2016 Sep.

30.

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2016 Oct 14;90(21):10022-10038. Print 2016 Nov 1.

31.

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Hervé PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eléouët JF, Riffault S.

Nanomedicine. 2017 Feb;13(2):411-420. doi: 10.1016/j.nano.2016.08.006. Epub 2016 Aug 20.

32.

Data publication with the structural biology data grid supports live analysis.

Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Fromme JC, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P.

Nat Commun. 2016 Mar 7;7:10882. doi: 10.1038/ncomms10882.

33.

Pre-fusion structure of a human coronavirus spike protein.

Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB.

Nature. 2016 Mar 3;531(7592):118-21. doi: 10.1038/nature17200.

34.

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS.

Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.

35.

Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers TH, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS.

Nat Chem Biol. 2016 Feb;12(2):87-93. doi: 10.1038/nchembio.1982. Epub 2015 Dec 7.

36.

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS.

Sci Transl Med. 2015 Oct 14;7(309):309ra162. doi: 10.1126/scitranslmed.aac4241.

37.

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JP.

Nat Commun. 2015 Sep 3;6:8143. doi: 10.1038/ncomms9143.

38.

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.

Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS.

PLoS Pathog. 2015 Jul 10;11(7):e1005035. doi: 10.1371/journal.ppat.1005035. eCollection 2015 Jul.

39.

Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.

40.

A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.

Stewart-Jones GB, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, Sastry M, Soto C, Yang Y, Zhang B, Chen L, Chuang GY, Georgiev IS, McLellan JS, Srivatsan S, Zhou T, Baxa U, Mascola JR, Graham BS, Kwong PD.

PLoS One. 2015 Jun 22;10(6):e0128779. doi: 10.1371/journal.pone.0128779. eCollection 2015.

41.

Novel antigens for RSV vaccines.

Graham BS, Modjarrad K, McLellan JS.

Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Review.

42.

Authors' reply to Wardlaw and Berge.

Alper BS, Malone-Moses M, McLellan JS, Prasad K, Manheimer E.

BMJ. 2015 Apr 7;350:h1795. doi: 10.1136/bmj.h1795. No abstract available.

PMID:
25851154
43.

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

McLellan JS.

Curr Opin Virol. 2015 Apr;11:70-5. doi: 10.1016/j.coviro.2015.03.002. Epub 2015 Mar 26. Review.

44.

Thrombolysis in acute ischaemic stroke: time for a rethink?

Alper BS, Malone-Moses M, McLellan JS, Prasad K, Manheimer E.

BMJ. 2015 Mar 17;350:h1075. doi: 10.1136/bmj.h1075. No abstract available.

PMID:
25786912
45.

Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis GK, Pazgier M.

J Virol. 2014 Nov;88(21):12895-906. doi: 10.1128/JVI.02194-14. Epub 2014 Aug 27.

46.

Infection with MERS-CoV causes lethal pneumonia in the common marmoset.

Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, Thomas MJ, van Doremalen N, Haddock E, Nagy L, LaCasse R, Liu T, Zhu J, McLellan JS, Scott DP, Katze MG, Feldmann H, Munster VJ.

PLoS Pathog. 2014 Aug 21;10(8):e1004250. doi: 10.1371/journal.ppat.1004250. eCollection 2014 Aug. Erratum in: PLoS Pathog. 2014 Sep;10(9):e1004431.

47.

Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.

van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, Kinne J, McLellan JS, Zhu J, Munster VJ.

J Virol. 2014 Aug;88(16):9220-32. doi: 10.1128/JVI.00676-14. Epub 2014 Jun 4.

48.

Structure and function of respiratory syncytial virus surface glycoproteins.

McLellan JS, Ray WC, Peeples ME.

Curr Top Microbiol Immunol. 2013;372:83-104. doi: 10.1007/978-3-642-38919-1_4. Review.

49.

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD.

Science. 2013 Nov 1;342(6158):592-8. doi: 10.1126/science.1243283. Erratum in: Science. 2013 Nov 22;342(6161):931.

50.

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies.

Amin MN, McLellan JS, Huang W, Orwenyo J, Burton DR, Koff WC, Kwong PD, Wang LX.

Nat Chem Biol. 2013 Aug;9(8):521-6. doi: 10.1038/nchembio.1288. Epub 2013 Jun 30.

Supplemental Content

Loading ...
Support Center